OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Headache and Pain is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis	458
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i	228
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	148
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts	108
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database	103
Development and validation of a novel model for characterizing migraine outcomes within real-world data	96
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	94
Episodic headache with spontaneous hypothermia reveal Shapiro’s syndrome variant with effectiveness of clonidine therapy	86
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy	78
Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial	71
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine	63
Interictal osmophobia is associated with longer migraine disease duration	61
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention	59
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience	56
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition	55
Altered functional connectivity of the right caudate nucleus in chronic migraine: a resting-state fMRI study	53
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies	51
Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists	50
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients	50
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study	47
The economic and personal burden of cluster headache: a controlled cross-sectional study	47
Long term evaluation of a multidisciplinary trigeminal neuralgia service	47
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months	46
Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine	46
Altered speech patterns in subjects with post-traumatic headache due to mild traumatic brain injury	44

Enhanced functional connectivity between habenula and salience network in medication-overuse headache complicating chronic migraine positions it within the addiction disorders: an ICA-based resting-st	44
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model	43
Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey	41
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments	40
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials	40
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance	39
Whole-brain morphological alterations associated with trigeminal neuralgia	39
Cerebral perfusion variance in new daily persistent headache and chronic migraine: an arterial spin-labeled MR imaging study	37
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis	37
Correction to: Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists	37
Correction to: Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea	36
Correction to: CGRP induces migraine-like symptoms in mice during both the active and inactive phases	35
Burden of tension-type headache in the Middle East and North Africa region, 1990-2019	35
Post-traumatic trigeminal neuropathy: correlation between objective and subjective assessments and a prediction model for neurosensory recovery	34
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension	34
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana	33
Is there a causal relationship between stress and migraine? Current evidence and implications for management	32
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study	31
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms	31
Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache	29
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism	29
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II	29
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update	28
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study	28
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	28
Resting-state magnetoencephalographic oscillatory connectivity to identify patients with chronic migraine using machine learning	28
Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis	28
Association between migraine and cognitive impairment	27
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model	27
The chronobiology of migraine: a systematic review	26
Time is of the essence in headache measurement. A response to Gil-Gouveia	25
Insular functional connectivity in migraine with aura	25
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study	25
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study	25
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study	24
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study	24
The sensitivity to change of the cluster headache quality of life scale assessed before and after deep brain stimulation of the ventral tegmental area	24
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report	24
The bidirectional temporal relationship between headache and affective disorders: longitudinal data from the HUNT studies	24
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	24
Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress	24
InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers	24
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials	23
Angioarchitectural features amongst patients with unruptured brain arteriovenous malformations presenting with headache: findings from a single center retrospective review of 76 patients	23
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2	23
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study	23
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	23
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients	23
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	23
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank	23

Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	23
Correction to: Medication overuse and drug addiction: a narrative review from addiction perspective	22
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	22
Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study	22
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine	22
Dynamic brainstem and somatosensory cortical excitability during migraine cycles	21
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	21
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice	21
The applicability research of the diagnostic criteria for 6.7.2 angiography headache in the international classification of headache disorders-3rd edition	21
Tracking the evolution of non-headache symptoms through the migraine attack	21
Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels	21
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	20
Metabolic profile changes in serum of migraine patients detected using 1H-NMR spectroscopy	20
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials	20
Age-related differences in resting state functional connectivity in pediatric migraine	20
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study	20
Association between suicidal risks and medication-overuse headache in chronic migraine: a cross-sectional study	20
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine	19
Genome-wide analyses identify novel risk loci for cluster headache in Han Chinese residing in Taiwan	19
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study	19
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	19
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study	19
Exploring the neurobiology of the premonitory phase of migraine preclinically – a role for hypothalamic kappa opioid receptors?	19
Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies	19
Amplitude of low-frequency fluctuation after a single-trigger pain in patients with classical trigeminal neuralgia	19
Avoid or seek light – a randomized crossover fMRI study investigating opposing treatment strategies for photophobia in migraine	19
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure	19
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial	19
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study	19
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	18
Altered static and dynamic functional network connectivity in post-traumatic headache	18
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies	18
Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions	18
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine	17
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia	17
Aberrant cerebral blood flow in tinnitus patients with migraine: a perfusion functional MRI study	17
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study	17
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks	17
Measuring interictal burden among people affected by migraine: a descriptive survey study	17
Migraine and neuroinflammation: the inflammasome perspective	17
Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study	17
Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors	17
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study	17
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	17
Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series	17
Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary	16
Mild traumatic brain injury affects the features of migraine	16
Functional connectivity and structural changes of thalamic subregions in episodic migraine	16
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial	16
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology	16
Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup	16
Characteristics of N400 component elicited in patients who have migraine with aura	16
Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury	16
Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study	16
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke	16
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms	15
Expression of vasopressin and its receptors in migraine-related regions in CNS and the trigeminal system: influence of sex	15
Serum CGRP in migraine patients using erenumab as preventive treatment	15
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study	15
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)	15
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study	15
Persistent headache after first-ever ischemic stroke: clinical characteristics and factors associated with its development	15
Regional cerebral blood flow as predictor of response to occipital nerve block in cluster headache	15
Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan	15
Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome	15
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China	15
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients	15
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	14
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies	14
Assessment of normalized cerebral blood flow and its connectivity with migraines without aura during interictal periods by arterial spin labeling	14
Altered brain functional network dynamics in classic trigeminal neuralgia: a resting-state functional magnetic resonance imaging study	14
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	14
Reversible cerebral vasoconstriction syndrome (RCVS): an interesting case report	14
Medication overuse and drug addiction: a narrative review from addiction perspective	14
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study	14
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-2019	14
CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater	14
Investigating the relationships between the burden of multiple sensory hypersensitivity symptoms and headache-related disability in patents with migraine	14
Headache service quality evaluation: implementation of quality indicators in primary care in Europe	14